Albumin recovery time may forecast surgical outcomes
NCT ID NCT07263061
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tracks 1,000 patients undergoing major liver, pancreas, or bile duct surgery to see if the time it takes for their albumin levels to return to normal can predict complications and length of hospital stay. Albumin is a protein that drops after surgery due to inflammation. Researchers will measure how quickly it rises without extra albumin supplements. The goal is to find a simple, early marker of recovery. No new treatment is being tested.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors identify patients at higher risk of complications after major liver or pancreas surgery, allowing for earlier support.
- What could go wrong
- This is an observational study, not a treatment trial. It only looks for patterns, so it cannot prove cause and effect. Results may not apply to all surgery types or hospitals.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 1,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2025
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
All patients undergoing major Hepato pancreatico Biliary surgeries.
- Ages
-
13 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. All patients undergoing major Hepato pancreatico Biliary surgeries. 2. Patients who are more than 12 years of age 3. Retrospective arm - Data from 2010 Exclusion Criteria: 1. Patients who refuse or are unable to give consent. 2. Patients with Nephrotic syndrome, Protein losing enteropathies, Inflammatory bowel 3. Disease, Chronic Liver Disease. 4. Emergency Surgeries
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bile duct diseases are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
ILBS
RECRUITINGNew Delhi, National Capital Territory of Delhi, 110070, India
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could fasting ease the misery of pancreatitis?
- Could a heart monitor during surgery shield patients from hidden cardiac harm?
- Can a new drug outperform standard care for a rare liver disease in teens?
- A drop of blood could spot a deadly liver disease in newborns
- Robotic surgery from miles away: could remote operations match On-Site care?
- AI assistant could spot hidden liver and pancreas cancers earlier